Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone + carnitine vs pioglitazone + vitamin E in non-alcoholic fatty liver disease
IRCT20190701044062N8Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Oct 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of pioglitazone, levocarnitine and vitamin e in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Tabriz University of Medical Sciences. Started Oct 2019; status: completed.
02
Drugs
pioglitazonelevocarnitinevitamin e
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20190701044062N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190701044062N8.